Image

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

Recruiting
18 years of age
Female
Phase 2

Powered by AI

Overview

A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.

Eligibility

Inclusion Criteria:

  • Woman ≥ 18 years
  • Signed and written informed consent.
  • Histologically-confirmed primary or recurrent squamous cell carcinoma vulvar cancer FIGO stage Ib - IVa, T1b or higher, any N, M0.
  • Local tumour through which the size or localization implies requirement of treatment through primary chemoradiation or surgery consisting of extensive surgery (meaning surgery damaging pelvic organs or exenterative surgery). This can imply;
    • T1b or larger tumour with (irresectable) groin metastases
    • T1b or larger tumour with a close relationship to and/or involvement of the urethra or anal sphincter
  • World Health Organization performance status of 0-2
  • Adequate haematological function defined by platelet count >100x10E9/L, absolute leukocyte >3X10E9/L or neutrophil count (ANC) >1.5x10E9/L, and hemoglobin >6.0 mmol/L
  • Adequate hepatic function defined by a total bilirubin level ≤1.5x the upper limit of normal (ULN) range and ASAT and ALAT levels ≤2.5x ULN for all subjects
  • Adequate renal function defined by an estimated creatinine clearance ≥50mL/min according to the Cockroft-Gault formula (or local institutional standard method)
  • Beta HCG level of 14 mIU/mL or below for women of childbearing potential
  • Highly effective contraception for patients if the risk of conception exists

Exclusion Criteria:

  • Patients with highly suspicious or positive metastases to the pelvic lymph nodes
    • Patients eligible for radical local excision without involvement of other organs
  • Any psychiatric condition that would prohibit the understanding or rendering of

    informed consent

  • Prior radiotherapy to the pelvis or groin area limiting full dose chemoradiation according to protocol
  • Existing neuropathy which will hinder the intake of chemotherapy

Study details

Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva

NCT05905315

The Netherlands Cancer Institute

30 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.